When Abby Schneidermans brother was killed in a car accident, her family was crushed by grief. They were also overwhelmed by trying to get his affairs in order posthumously. In an instant, everything changed for my family, she says. We had no idea what to do, we were in a daze as so many people are. They couldnt locate certain documents or and didnt know where to turn.
A strategic mistake made six years ago by celebrity CEO Ron Johnson continues to haunt popular retailer JC Penney, as evidenced by the ongoing sluggish sales growth and store closings that have made the company smaller—a fraction of what it once was.
Meanwhile, investors have been bailing out from the company’s stock,....More>>>
For some investors, they’ve created small fortunes. For others, they’ve brought nothing but misery. For all investors, though, there’s no denying the fact that biotech stocks have kept things interesting if only because they can always supply a binary even traders can treat like a coin toss. The third quarter of 2017 isn’t going to be any different.
Our best stocks to buy now list for June is heavy on tech. That makes sense, of course. As Money Morning Director of Technology & Venture Capital Research Michael Robinson tells us, the road to wealth is paved with tech.
Our Money Morning investing and trading experts have picked four companies we like right now. Two of them have their feet in both the high-tech pharmaceuticals....More>>>
Every new generation of wireless networks delivers faster speeds and more functionality for devices. 1G brought us the very first cell phones, 2G let us text for the first time, 3G brought us online, and 4G brought us the speeds we enjoy today. But as more devices come online, 4G networks have just about reached their limit of what they’re capable of, at a time when connected devices are growing....More>>>
MannKind (NASDAQ:MNKD) investors have had an interesting week. The company announced that Mike Castagna would be the new CEO, and followed that news with an announcement of a deal to move forward on possible Afrezza sales in Brazil. Today the company announced that it has engaged a strategic partner to explore possible deals surrounding its Technosphere technology. Locust Walk will seek....More>>>
Nintendo (NASDAQOTH:NTDOY) is off to a good start in 2017. The new Switch console is selling extremely well, and the company is beginning to make a push into mobile gaming in order to reach the maximum audience with its classic game brands like Mario.
Learning from mistakes
One reason for the Switch’s success is the corrections Nintendo made with its marketing compared to its....More>>>
Back in October 2016, the Federal Communications Commission (FCC) imposed privacy rules that required Internet and mobile phone corporations to get consent from their customers before sharing personal data with advertisers.
But yesterday (March 28) — amid news of the Russian spy scandal, the failed healthcare vote, the Gorsuch hearing, and more — the House voted to repeal....More>>>
"When was the last time a sector or an industry went down six years in a row?" I asked my good friend Meb Faber at lunch in New York last November. Meb is the guy to ask… He is one of the smartest, most respected minds on Wall Street. And he has crunched the numbers going back decades. "Six down years? It NEVER happens," he said. "But coal stocks ended....More>>>
On Friday, small cap cancer stock Mirati Therapeutics (NASDAQ: MRTX) surged 135.79% inheavy trading volume after announcing positive lung cancer treatment trial results. Mirati Therapeutics is a clinical-stage biotechnology company focused on developing a pipeline of targeted oncology products in
Shares of Ignyta (NASDAQ:RXDX) have more than doubled over the past year, with news in May that the company received the coveted Breakthrough Therapy Designation for entrectinib providing momentum for the next leg up.
To begin this article, let's take a trip back to July 27th. AstraZeneca (NYSE:AZN) investors received the worst possible news with the news headline "AstraZeneca lung cancer immunotherapy trial failure sends shares plunging" effectively summing everything up. Shares absolutely
Just as the body's normal stem cells renew and sustain organs and tissue, cancer stem cells do the same for tumors. Large cap drugmaker AbbVie (NYSE:ABBV) is taking the lead in developing drugs to go after cancer stem cells, and long-term investors could enjoy the payoff.
It’s still a difficult time for income investors. Interest rates are predicted to rise in 2017, and Treasury yields are creeping up. But a 10-year Treasury bond pays less than 2.6% interest annually; guaranteed investments such as CDs and checking accounts offer returns of barely 1% a